11.12.07
Synairgen, a company developing novel therapies for asthma and COPD, has selected Alpha Biologics to help with the advancement of its growth factor drug development program. Alpha will develop a scaleable manufacturing process for Synairgen's optimized growth factor to support preclinical and clinical development. Richard Marsden, Synairgen's managing director, said, "We have significant confidence in our growth factor drug development program for asthma to restore barrier function in patients. Initiating the development of a scaleable manufacturing process is another significant milestone for the program."
Cambridge, UK-based Alpha Biologics is an independent contract biomanufacturing organisation offering FDA/EMEA cGMP compliant services to the worldwide pharmaceutical and biotechnology industry.
Cambridge, UK-based Alpha Biologics is an independent contract biomanufacturing organisation offering FDA/EMEA cGMP compliant services to the worldwide pharmaceutical and biotechnology industry.